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Background:  Colon  and  colorectal  cancer  (CRC)  research  has  entered  a new  era  with  recent
updates  of molecular  events  and  prognostic  markers.  Among  other  prognostic  markers,
exaggerated  expression  of  nuclear  CCND1  has  key  role  in  tumour  pathogenesis  and  metas-
tases of CRC  and  has also  been  claimed  to  predict  response  to treatment.
Objectives:  This  study  was  designed  to evaluate  the  prognostic  and  predictive  value  of
CCND1 in  CRC  and  the correlation  of  CCND1  expression  with  the  different  clinicopatho-
logical  parameters.
Methods:  Parafﬁn  blocks  from  117  primary  CRC  were  retrieved  from  the  archives  of the
Department  of Pathology  at King  Abdulaziz  University.  Tissue  microarrays  were  designed
and constructed.  The  immunostaining  of CCND1  was  performed  and  analysed.
Results: There  were  more  cases  with  low  nuclear  immunoexpression  of CCND1in  both  pri-
mary tumours  and nodal  metastasis  (p < 0.001).  Cyclin  D1 did  not  show  association  with
clinicopathological  features  except  with  lymphovascular  invasion.  Low  nuclear  immuno-
expression  of  CCND1  was  associated  with  negative  lymphovascular  invasion  (p = 0.046).
There  was  no  statistically  signiﬁcant  correlation  between  CCND1  immunoexpression  and
survival probability  (Log  Rank  =  2.474,  p  = 0.116).
Conclusion:  Our  study  indicates  that CCND1  immunoexpression  cannot  be  used  as  a pre-
dictor of survival  in CRC.  It also  shows  no  signiﬁcant  correlation  with  clinicopathological
features  except  with  lymphovascular  invasion.
di  Soci©  2015  Sau
1. IntroductionNew advances in the molecular pathology of cancer over
the past two decades described key signalling pathways
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involved in malignant progression of colorectal carcinoma
(CRC). Upregulation of nuclear cyclin D1 (CCND1) plays
an important role in pathogenesis and metastases of CRC
[1,2]. High nuclear CCND1 expression occurs in one-third
of CRC [3]. Sensitive biological markers are needed to max-
imise the beneﬁt of therapeutic approaches in CRC [4].
Study of molecular events and prognostic factors is there-
fore important in CRC research. In CRC cell lines, CCND1
downregulation has anti-APC mutation effect in transgenic
mice [5].
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Table 1
Clinicopathological parameters of CRC (n = 117) patients attending King
Abdulaziz University Hospital, Jeddah.
Parameter Number (%)
Sex Male 59 (50.4%)
Female 58 (49.6%)
Grade Well-differentiated 32 (27.4%)
Moderately differentiated 70 (59.8%)
Poorly differentiated 15 (12.8%)
Age <60 years 58 (49.6%)
≥60 years 59 (50.4%)
Tumour
location
Right colon 37 (31.6%)
Left colon 71 (60.7%)
Rectum 9 (7.7%)
Tumour size <5 cm 51 (43.6%)
≥5 cm 66 (56.4%)
Primary
tumour
T1  2 (1.7%)
T2  21 (17.9%)
T3  87 (74.4%)
T4  7 (6%)
Nodal
metastasis
Negative 68 (58.1%)
Positive 49 (41.9%)
Distant
metastasis
Negative 86 (73.5%)
Positive 31 (26.5%)
Lymphovascular
invasion
Negative 104 (88.9%)
Positive 13 (11.1%)
Margin status Free 112 (95.7%)
Involved 5 (4.3%)
Relapse No relapse 79 (67.5%)
Relapse 38 (32.5%)
T1: Tumour involves submucosa.
T2: Tumour involves muscularis propria.
T3: Tumour crosses through the muscularis propria into the subserosa orJ. Al-Maghrabi et al. / Journal of Mic
CCND1 interacts with other proteins such as DNA repair
roteins [6,7]. Between CCND1a and CCND1b, only CCND1a
ransfer to nuclear chromatin sufﬁciently provokes DNA
amage response (DDR) [6]. Reduction of endogenous
CND1 in CRC cells also reduces the DDR in response to
-FU treatment [6].
Arrays of core biopsies obtained from parafﬁn-
mbedded tissues are called as tissue microarrays (TMAs).
hese arrays serve as an excellent means for high-
hroughput gene or protein expression analysis among
opulation based large study groups of cancer patients
n a single slide. This technology is increasingly being
sed for the high throughput analysis of the diagnostic,
redictive, or prognostic value of biomarkers in tissue spec-
mens. Immunohistochemical (IHC) methods seem to be
ost ideal for validation since the tissue based studies are
resent in the form of formalin ﬁxed parafﬁn-embedded
issue blocks [8]. The principle of TMA  is miniaturisation
nd a high throughput gene or protein expression analysis.
MA  technology has been implicated widespread in cancer
tudies including CRC [9,10].
The aim of this study was to evaluate the prognostic
nd predictive value of cyclin D1 in colorectal carcinomas
nd the correlation of cyclin D1 expression with the differ-
nt clinicopathological features in patients attending King
bdulaziz University Hospital from 1995 to 2012.
. Materials and methods
.1. Patients
The study included parafﬁn wax blocks of tumour from
17 patients with CRC and 29 corresponding to nodal
etastases. Blocks were collected from the Department of
athology at King Abdulaziz University, Jeddah, Saudi Ara-
ia from 1995 to 2012. Patients’ demographic data is listed
n Table 1. The study was  approved by the Research Com-
ittee of the Biomedical Ethics Unit, Faculty of Medicine,
ing Abdulaziz University. Disease-free survival (DFS) was
alculated as the time from diagnosis to the appearance of
ecurrent disease (or date last seen disease-free).
.2. Tissue microarray (TMA) construction
TMAs were constructed as described by Kallioniemi
11]. New sections were prepared from the donor blocks
nd stained with haematoxylin–eosin (H&E). These slides
ere used to guide the samplings from morphologically
epresentative regions of the tissues. TMA  block was con-
tructed using one punch from each colorectal carcinoma
epending on the most cellular region of the tumour
arked by a pathologist. A tissue arrayer (Tissue Micro
rray Master 3D Histech, EU) was used to create TMAs.
.3. Immunohistochemical staining
Immunostaining staining for the CCND1 to sections of
he formalin-ﬁxed colonic biopsies microarray was carried
ut. Four micrometre thick sections were prepared from
arafﬁn blocks and mounted on positive charged slides.
ections were deparafﬁnised and rehydrated. Slides wereinto non-peritonealised pericolic or perirectal tissues.
T4: Tumour directly involves other organs/structures, and/or perforates
visceral peritoneum.
immersed in H2O2 (0.3%) for 12 min  to block the endoge-
nous peroxidase activity. Slides were then pre-treated in
microwave oven in 10 mM citrate buffer (pH 6) for three
cycles of 5 min  each. Immunostaining with CCND1 using
Ventana “ready to use” kit was performed in an automated
immunostainer (BenchMark XT, Ventana Medical Systems
Inc., Tucson, AZ, USA) according to the instruction manual
attached. Subsequently, sections were washed, counter-
stained with haematoxylin and mounted. Negative control
(by substitution of primary antibody with Tris-buffered
saline) was used. Positive control was  used as those from
breast cancer.
2.4. Scoring of immunohistochemistry
The intensity of the staining was  graded as: 0, no stain-
ing; 1, mild staining; 2, moderate staining; and 3, marked
staining. The percentage of staining was reported as: 0, less
than 5%; 1, 5–25%; 1, 26–50%; 3, 51–75%; and 4, more than
75%. The ﬁnal score was  calculated by the sum of inten-
sity and percentage as follow: 0, 0–1; 1, 2; 2, 3–5; 3, 6–7
[12]. For statistical purpose, CCND1 immunoscores were
dichotomised as low expression (0 and 1), and high expres-
sion (2 and 3).
64 J. Al-Maghrabi et al. / Journal of Microscopy and Ultrastructure 3 (2015) 62–67
Table  2
Categories of immunoexpression of CCND1 in primary CRC and nodal
metastases among patients attending King Abdulaziz University Hospital,
Jeddah.
Primary
tumour
(n = 117)
Nodal
metastasis
(n = 29)
p value
Low expression 90 (76.9%) 20 (69%) 0.34**
High expression 27 (23.1%) 9 (31%)
* *
Table 4
Multivariate analysis for CCND1 immunoexpression among CRC patients
attending King Abdulaziz University Hospital, Jeddah.
Variable Adjusted R square p value
Nodal metastasis 0.006 0.552
Distant metastasis 0.002 0.365
Surgical resection margins 0.000 0.322
Lymphovascular invasion 0.036 0.025p  value <0.001 <0.001
* One sample non-parametric chi-square test.
** Mann–Whitney test.
2.5. Statistical analysis
Differences between two groups of patients on one vari-
able were tested by using Mann–Whitney test. To test
association procedure in three groups of patients on one
independent variable the Kruskal–Wallis test was  used.
Chi-square was used to test association between CCND1
expression and clinicopathological features. Multivariate
analysis was used to predict nodal metastasis, distant
metastasis, surgical resection margins, lymphovascular
invasion, and recurrence in relation immunoexpression of
cyclin D1. The Kaplan–Meier procedure was used to cal-
culate the survival probabilities and the Log Rank test was
used to compare the difference between survivals. The end-
point for patients was death from tumour (disease-free).
Table 3
Distribution of high CCND1 immunoexpression (n = 27) in relation to clinicopath
versity Hospital, Jeddah.
Grade Well-differentiated 
Moderately differentiated 
Poorly differentiated 
Sex Male 
Female 
Age >60  years 
≥60 years 
Tumour
location
Right colon 
Left colon 
Rectum 
Tumour size <5 cm 
≥5 cm 
Depth of
invasion (pT)
T1 
T2 
T3  
T4  
Nodal metastasis
(n = 29)
Negative 
Positive 
Distant
metastasis
Negative 
Positive 
Lymphovascular
invasion
Negative 
Positive 
Margin status Free 
Involved 
Relapse Relapse 
No relapse 
* Kruskal–Wallis test.
** Chi square test.Recurrence 0.000 0.311
Disease-free survival (DFS) was calculated as the time from
diagnosis to the appearance of recurrent disease (or date
last seen disease-free). Statistical procedures were per-
formed using SPSS® Release 16.0. Statistical signiﬁcance
was  determined at p value of ≤0.05 and was 2-sided.
3. Results
In Table 2 we present the categories of immunoexpres-
sion in primary CRC and nodal metastases. Twenty-seven
patients showed high CCND1 immunoexpression and its
correlation to clinicopathological parameters is presented
in Table 3. In Table 4 we present the multivariate analysis
for CCND1 immunoexpression. Fig. 1 presents the CCND1
nuclear expression in CRC.
ological parameters among CRC patients attending King Abdulaziz Uni-
Number (%) p value
10 (37%) 0.257*
14 (51.9%)
3 (11.1%)
13 (48.1%) 0.829**
14 (51.9%)
15 (55.6%) 0.517**
12 (44.4%)
5 (18.5%) 0.087*
19 (70.4%)
3 (1.1%)
12 (40%) 0.545**
15 (60%)
2 (7.4%) 0.441*
5 (18.5%)
18 (66.7%)
2 (7.4%)
16 (59.3%) 0.537**
11 (40.7%)
22 (81.5%) 0.269**
5 (18.5%)
21 (77.8%) 0.046**
6 (22.2%)
25 (92.6%) 0.326**
2 (7.4%)
20 (74.1%) 0.268**
7 (25.9%)
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.1. Immunohistochemistry of CCND1
There were more cases with low CCND1 immuno-
taining in both primary tumours and nodal metastasis
p < 0.001). There was no difference between CCND1 immu-
oexpression in primary tumours and nodal metastasis.
.2. Relation of CCND1 immunostaining to
linicopathological features and survival probability
CCND1 immunoexpression did not show any asso-
iation with clinicopathological features except with
ymphovascular invasion. Low nuclear expression of
CND1 was associated with negative lymphovascular inva-
ion (p = 0.046). There was also no relation between
CND1 immunostaining and survival probability (Log
ank = 2.474, p = 0.116) (Fig. 2).
. DiscussionColorectal carcinoma (CRC) is one of the most frequent
ancers in the Western world and with the changes of life
ehaviours; CRC has reportedly become more and more
requent in China [12,13]. CRC is the third most commonC and D) High nuclear CCDN1 expression (IHC, 200×).
cancer in men  and the second in women worldwide. Almost
55% of the cases occur in more developed regions [14].
According to the Saudi Arabian National Cancer Registry,
CRC is accounting for 11.3% of all newly diagnosed cases in
year 2009. This cancer ranked ﬁrst among male population
and third among female in Saudi population.
The pathogenesis and progression of CRC are results
of multiple genetic alterations occurring in a systematic
fashion. In the past decade research has identiﬁed multiple
molecules regulating CRC in an effort to highlight biologi-
cally aggressive tumours and appropriately select patients
for adjuvant systemic or targeted therapies [12].
The role of CCND1 is known as a key player molecule in
control of the shift of cell cycle from phase G1 to S phase
by pRb mediation. CCND1/Cyclin-Dependent Kinase (CDK)
4–6 complexes initiate the phosphorylation of pRb and
cyclin E/CDK2 complex completes the procedure in late G1
phase. Alterations in cyclin and CDK expression result in
increased cell proliferation and contribute to malignancy
[15]. CCND1 protein stimulated cellular proliferation and
contributes to oncogenesis [16]. CCND1 gene is disrupted
in the cancer cell genome usually by the process of gene
ampliﬁcation or chromosome translocation which may  be
involved in malignancy [17]. In humans over-expression
66 J. Al-Maghrabi et al. / Journal of MicroscopyFig. 2. Correlation between disease-free survival curve (Kaplan–Meier)
and CCND1 immunoexpression. (1) Low CCND1 immunoexpression; (2)
high CCND1 immunoexpression (Log Rank = 2.474, p = 0.116).
of CCND1 is seen in many tumours including colorectal
cancers [12].
Although lots of studies have been performed on CCND1
expression in CRC, they seem to be ending up with
conﬂicting conclusions. Some found that CCND1 is of
prognostic importance in CRC. However, they did ﬁnd asso-
ciation between CCND1 and survival. The ﬁndings were
also conﬂicting regarding which is favourable low or high
CCND1 [1,4,18–22]. Since all these studies on CCND1 have
used immunostaining the variability in results could be
due to the use different anti-CCND1 antibody clones and
using different cut off points for immunostaining scoring.
Other factors that differ among these studies are the num-
ber of cases, and techniques used. However, the results in
the present study are in concordance with a previous study
[20] supporting the observations that there seems to be no
statistically signiﬁcant correlation between CCND1 expres-
sion and overall survival probability or clinicopathological
features.
Ogino et al. [22] examined the relation between CCND1
expression and survival of patients in stage I to IV CRC.
They found that CCND1 overexpression was independent
of clinicopathological features and other related molecu-
lar variables such as p53, p21, p27, KRAS, BRAF, LINE-1
methylation, MSI, and the CIMP. All of these characteris-
tics are potential confounders in analysis of tumoral CCND1
status and patient survival. They concluded that CCND1
expression in colon cancer is associated with superior prog-
nosis [22]. In addition, CCND1 expression in colon cancer is
related with microsatellite instability (MSI), the CpG island
methylator phenotype (CIMP), and BRAF mutation [23].Studies have suggested strong association of CCND1
expression with prolonged survival among male with
CRC [19] adding further momentum to the existing evi-
dence that CRC is a hormone-dependent cancer, for which and Ultrastructure 3 (2015) 62–67
prognostic and treatment predictive molecular biomarkers
should be evaluated based on patients gender [19].
Zhang et al. [24] reported that knockdown of paired box
(PAX2), a transcription factor, inhibits the activity of AP-1, a
transcription factor that induces CCND1 expression, imply-
ing that PAX2 induces CCND1 through AP-1 (a transcription
factor) in CRC. PAX2 plays a critical role in embryogene-
sis. When aberrantly expressed in adult tissues, it generally
exhibits oncogenic properties [24]. The mRNA cap-binding
protein, eukaryotic initiation factor 4E (eIF4E) is critical
in translation initiation due to its limiting amount in the
cell. eIF4E levels were moderately correlated with VEGF
and CCND1 in colon cancer supporting the role for eIF4E
in translational regulation of proteins related to angiogen-
esis and growth [25]. Myklebust et al. [4] investigated the
roles of CCND1a and CCND1b, as prognostic markers in CRC
in a cohort. In CRC, combined stage 1 and 2 in addition
to stage III, CCND1a nuclear overexpression was  found to
be a predictive marker for beneﬁt from 5-ﬂuorouracil and
levamisole comparable to surgery. Contrary, low nuclear
immunoexpression of CCND1a has no effect on treatment
outcome [4]. CCND1b has neither prognostic nor predictive
association in CRC [4,25].
Limitations of the current study include: TMA  uses only
a small part of a tissue specimen that may  not be represent
the actual gene or protein nature and distribution within
a tumour which is also prone to exhibit heterogeneous
territorial staining patterns [3,12,26]. Regarding using
immunohistochemistry to highlight CCND1, although the
method is sensitive, results are not quantitative and there
are no standardised scoring systems or uniformly accepted
threshold for positivity which are major limitations to
interpretations.
5. Conclusion
Our study indicates that CCND1 immunoexpression
cannot be used as a predictor of survival in CRC. It also
shows no signiﬁcant correlation with clinicopathological
features except with lymphovascular invasion. However,
further validation studies for the prognostic role of CCND1
in CRC are required clinically.
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